Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.55 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.48 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.48 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.48 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | CPA1 | P15085 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7262370 | 0.83 | MME (0.56) | MMECACNA2D1CACNB3CACNA1CPGR | |
| SCHEMBL5870523 | 0.83 | MME (0.56) | MMECACNA2D1CACNB3CACNA1CPGR | |
| SCHEMBL307076 | 0.83 | MME (0.56) | MMECACNA2D1CACNB3CACNA1CPGR | |
| SCHEMBL6744485 | 0.82 | FOLH1 (0.46) | MMECPA1TDP1FOLH1 | |
| SCHEMBL5672721 | 0.82 | KISS1R (0.61) | MMEKISS1RSLC1A3SLC1A2CPA1 | |
| SCHEMBL8053072 | 0.80 | MME (0.59) | MMECACNA2D1CACNB3CACNA1CPGR | |
| SCHEMBL27527680 | 0.79 | KISS1R (0.59) | MMEKISS1RSLC1A3SLC1A2CPA1 | |
| Ammonia Solution, Strong SCHEMBL27748255 | 0.79 | KISS1R (0.59) | MMEKISS1RSLC1A3SLC1A2CPA1 | |
| SCHEMBL15080402 | 0.79 | SLC1A3 (0.44) | MMECACNA2D1CACNB3CACNA1CPGR | |
| SCHEMBL10000212 | 0.79 | CACNA2D1 (0.52) | MMECACNA2D1CACNB3CACNA1CPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170151232-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | CURIA BUFFALO R&D, LLC | 2017-06-01 | — | — | US | disclosed |
| US-20140315790-A1 | AMINOTHIAZOLES AND THEIR USES | BUSHELL SIMON (US) | 2014-10-23 | — | — | US | disclosed |
| US-20130252883-A1 | Macrocycles and Their Uses | NOVARTIS AG (CH) | 2013-09-26 | — | — | US | disclosed |
| CN-102639513-A | Sphingosine kinase inhibitors | MERCK PATENT GMBH | 2012-08-15 | — | — | CN | disclosed |
| US-20120078349-A1 | COATED IMPLANT COMPOSED OF A BIOCORRODIBLE MAGNESIUM ALLOY | BIOTRONIK AG (CH) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252883-A1 | Macrocycles and Their Uses | MRPL21, CLPP, MLEC | MME 388/4885CACNA2D1 4768/4885CACNB3 3228/4885 |
| US-20140315790-A1 | AMINOTHIAZOLES AND THEIR USES | ABAT, AADAT, GOT2 | MME 497/4885CACNA2D1 3063/4885CACNB3 1250/4885 |
| US-20170151232-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | OPRM1, OPRK1, OPRD1 | MME 272/4885CACNA2D1 3247/4885CACNB3 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.